Sign in Subscribe
Vaccines

Alnylam Pharmaceuticals Files Suit Against Pfizer and Moderna for Patent Infringement

Strategic Insights

— 1 min read

Alnylam Pharmaceuticals has filed a lawsuit in the United States District Court for the District of Delaware against Pfizer and Moderna, accusing them of patent infringement related to the development of COVID-19 vaccines using messenger RNA (mRNA) technology. The patent in question, US Patent No. 11,246,933, relates to Alnylam's biodegradable cationic lipids that are essential for the success of mRNA COVID-19 vaccines. Alnylam is seeking fair compensation for the use of its technology, which was developed over a decade ago through extensive research and investment. The company has stated that it does not intend to seek an injunction or take action that would impede the production, sale, or distribution of the vaccines.

Key Takeaways:

  • Alnylam Pharmaceuticals has filed a lawsuit against Pfizer and Moderna in the United States District Court for the District of Delaware, accusing them of patent infringement related to the development of COVID-19 vaccines using mRNA technology.
  • The patent in question, US Patent No. 11,246,933, relates to Alnylam's biodegradable cationic lipids that are essential for the success of mRNA COVID-19 vaccines.
  • Alnylam is seeking fair compensation for the use of its technology, which was developed over a decade ago through extensive research and investment.
  • The company has stated that it does not intend to seek an injunction or take action that would impede the production, sale, or distribution of the vaccines.
  • Alnylam's commercial RNAi therapeutic products include ONPATTRO, GIVLAARI, OXLUMO, and Leqvio, which are being developed and commercialized by Alnylam's partner, Novartis.
  • Alnylam has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.
  • The company is executing on its "Alnylam P5x25" strategy to deliver transformative medicines in both rare and common diseases, benefiting patients around the world through sustainable innovation and exceptional financial performance.

Statistics:

  • The patent infringement lawsuit has been filed in the United States District Court for the District of Delaware.
  • The patent in question, US Patent No. 11,246,933, was developed over a decade ago through extensive research and investment.
  • Alnylam is seeking fair compensation for the use of its technology, which is essential for the success of mRNA COVID-19 vaccines.
  • The company has a deep pipeline of investigational medicines, including six product candidates that are in late-stage development.

Sources:

  • Alnylam Pharmaceuticals. "Alnylam Files Suit Against Pfizer and Moderna for Patent Infringement." BusinessWire, March 17, 2022.

Read more